To assess the safety, tolerability, immunogenicity and efficacy of the CAIV-T vaccine to protect childen receiving either a one-or two-dose primary vaccination against culture-confirmed influenza illness caused by subtypes antigenically similar to those contained in the vaccine or placebo (whether the subject received a one-or-two-dose primary vaccination regimen) and the end of the subsequent influenza season. This study has completed recruitment and we are waiting for sampling and the end of influenza season.
Showing the most recent 10 out of 515 publications